A randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of Arbaclofen in subjects with 16p11.2 deletion (16p del)

Project Type(s):

Principal Investigator(s):
Co-Investigator(s):

To examine the safety, tolerability, and efficacy of arbaclofen for the treatment of neurodevelopmental impairments in subjects with 16p11.2 deletion

Project Period:
April 1, 2020 — April 1, 2022

Funding Type(s):
Foundation

Funder(s):
Clinical Research Associates, LLC, and the Simons Foundation

Research Program(s):

Geographic Area(s):
National

Patient Population(s):
Adolescents, Children

Targeted Condition(s):
Autism Spectrum Disorder